Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05681468
Other study ID # Pro00123687
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 18, 2023
Est. completion date May 31, 2026

Study information

Verified date March 2024
Source University of Alberta
Contact Paulina Blanco Cervantes, MSc
Phone 7804929506
Email blancoce@ualberta.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to compare a healthy KETO diet supplemented with canola oil (KETO-Can) compared to a traditional KETO diet high in saturated fat (KETO-Sat) and low-fat diet (LFD) in adults at high risk of or diagnosed with type 2 diabetes. The main question[s] it aims to answer are: - Effects on CVD risk factors (plasma cholesterol, TG, ApoB100, glucose, insulin and HbA1C). - Effects on systemic inflammation and immune function. - Safety and adherence to interventions. Participants will be randomized into 1 of the dietary treatments during which they will follow a Keto or a low-fat diet. Comparisons among groups at 3 and 6 months of intervention will be conducted.


Description:

The ketogenic diet (KETO) is popular for weight loss and is gaining interest as a treatment for type 2 diabetes (T2D) because it is believed to help manage blood glucose and weight. However, KETO is often high in saturated fats (SFA), which may increase cholesterol and other cardiovascular (CVD) risk factors, such as inflammatory profile. Substituting a heart-healthy oil for SFA may improve these outcomes. The purpose of our study is to investigate the health beneficial effects of a healthy KETO diet supplemented with Canola oil, compared to a traditional Keto Diet and low-fat diet in adults at high risk of type 2 diabetes. Participants will be randomized to one of these three diets and will receive nutrition counselling during 6 months. Each month, participants will receive a 1-month supply of canola oil in the KETO-Can group, butter, coconut and palm oil in the KETO-Sat group and whole grain cereal and/or oatmeal in the LFD group to ensure compliance to key nutrients. Fasting blood samples will be taken at baseline, 3 and 6 months. Anthropometric measurements (weight (BW), waist circumference (WC), BMI), blood pressure (BP), systemic inflammation (CRP, IL-6, TNF-α, IL-18), immune function, cardiometabolic risk factors (TG, cholesterol, glucose, insulin and HbA1C) will be determined at each time point. A total of three 24h-recall questionnaires (2 weekdays and 1 weekend day) will be completed at each time point (baseline, 3 months, 6 months). Once a month (in between study visits) a 24h-recall will be completed before meeting the nutrition expert in order to personalize recommendations according to participants' respective diet groups. As in any nutritional study, adherence for nutrition study is a key factor and will be measured differently during the intervention. Menu examples will be provided for each group to facilitate adherence. Adherence to the study protocol will be assessed by (1) evaluation of monthly 24-h recall data (5 in total). Participants with 4 out of 5 recalls being within meeting dietary objectives will be considered highly compliant, 2 or less would be low compliance; (2) Ketosis state will be measured at each study visit using ketone strips to assess adherence to both KETO diets; (3) Participants will be asked to return any remaining food provided each month to determine the level of consumption. Finally, fatty acid composition in plasma (short-term) and red blood cells (RBCs; reflect the past 3 months) will be assessed to confirm adherence between the two keto diets.


Recruitment information / eligibility

Status Recruiting
Enrollment 175
Est. completion date May 31, 2026
Est. primary completion date May 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Having overweight or obesity and HbA1C = 5.7% at screening Exclusion Criteria: - Individuals with specific nutritional habits preventing them from adhering to nutritional recommendations - pregnant women - people on dialysis or recommended to follow a low-protein diet (base on glomerular filtration rate) - familial hypercholesterolemia or hypertriglyceridemia - transitioning trans-gender - transitioning menopausal women.

Study Design


Intervention

Other:
Keto-SAT
Nutrition counselling focused on Keto diet (saturated fat). 10% TE as carbohydrate (mainly from vegetables and whole grain products), protein between 20-30% TE and fat between 60-70%.
Keto-CAN
Nutrition counselling focused on Keto diet (unsaturated fat). 10% TE as carbohydrate (mainly from vegetables and whole grain products), protein between 20-30% TE and fat between 60-70%.
LFD
Nutrition counselling focused on low-fat diet. 30% total energy (TE) as fat, 50% TE as carbohydrates (primarily whole grains) and 17-20% TE protein (mainly lean sources).

Locations

Country Name City State
Canada University of Alberta Edmonton Alberta

Sponsors (1)

Lead Sponsor Collaborator
University of Alberta

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Adherence to diet interventions using 24-hour dietary assessment tool A validated online 24-recall questionnaire (ASA24) will be administered to participants to assess adherence to diets every month. 4 weeks
Other Change in fatty acid composition to confirm adherence to the diets at 3 months Total lipids in plasma, RBCs and PBMCs membranes will be extracted using Folch ratio 4:1 (chloroform:methanol (2:1): KCl). Extracted lipids are then methylated to create fatty acid methyl esters which will be measured by automated gas chromatography using an agilent 7890/8890 GC with a 100m CP-Sil 88 fused capillary column for long chain fatty acids. Total phospholipids and lipid classes in PBMCs membrane will be quantified using thin-layer chromatography and identified using internal standards. 3 months
Other Change in fatty acid composition to confirm adherence to the diets at 6 months Total lipids in plasma, RBCs and PBMCs membranes will be extracted using Folch ratio 4:1 (chloroform:methanol (2:1): KCl). Extracted lipids are then methylated to create fatty acid methyl esters which will be measured by automated gas chromatography using an agilent 7890/8890 GC with a 100m CP-Sil 88 fused capillary column for long chain fatty acids. Total phospholipids and lipid classes in PBMCs membrane will be quantified using thin-layer chromatography and identified using internal standards. 6 months
Primary Effect of diets on plasma triglycerides levels by comparing groups at 3 months of intervention (i.e. control low fat diet and the 2 keto groups) and changes over time within each group (i.e. baseline vs. 3 months). Assess triglycerides levels collecting blood samples in a fasting state. Triglycerides will be determined using commercially available equipment at a local laboratory (Roche Cobas c503). Measurements will be performed for between group comparison and within groups comparison to understand the effect of diets. 3 months
Primary Effect of diets on plasma triglycerides levels by comparing groups at 6 months of intervention (i.e. control low fat diet and the 2 keto groups) and changes over time within each group (i.e. baseline vs. 6 months). Assess triglycerides levels collecting blood samples in a fasting state. Triglycerides will be determined using commercially available equipment at a local laboratory (Roche Cobas c503). Measurements will be performed for between group comparison and within groups comparison to understand the effect of diets. 6 months
Primary Effect of diets on LDL-cholesterol levels by comparing groups at 3 months of intervention (i.e. control low fat diet and the 2 keto groups) and changes over time within each group (i.e. baseline vs. 3 months). Assess LDL-cholesterol levels collecting blood samples in a fasting state. LDL-Cholesterol levels will be determined using commercially available equipment at a local laboratory (Roche Cobas c503). Measurements will be performed for between group comparison and within groups comparison to understand the effect of diets. 3 months
Primary Effect of diets on LDL-cholesterol levels by comparing groups at 6 months of intervention (i.e. control low fat diet and the 2 keto groups) and changes over time within each group (i.e. baseline vs. 6 months). Assess LDL-cholesterol levels collecting blood samples in a fasting state. LDL-Cholesterol levels will be determined using commercially available equipment at a local laboratory (Roche Cobas c503). Measurements will be performed for between group comparison and within groups comparison to understand the effect of diets. 6 months
Secondary Effect of diets on blood glucose levels by comparing groups at 3 months of intervention (i.e. control low fat diet and the 2 keto groups) and changes over time within each group (i.e. baseline vs. 3 months). Assess blood glucose levels collecting blood samples in a fasting state. Blood glucose levels will be determined using commercially available equipment at a local laboratory (Roche Cobas c503). Measurements will be performed for between group comparison and within groups comparison to understand the effect of diets. 3 months
Secondary Effect of diets on blood glucose levels by comparing groups at 6 months of intervention (i.e. control low fat diet and the 2 keto groups) and changes over time within each group (i.e. baseline vs. 6 months). Assess blood glucose levels collecting blood samples in a fasting state. Blood glucose levels will be determined using commercially available equipment at a local laboratory (Roche Cobas c503). Measurements will be performed for between group comparison and within groups comparison to understand the effect of diets. 6 months
Secondary Effect of diets on insulin levels by comparing groups at 3 months of intervention (i.e. control low fat diet and the 2 keto groups) and changes over time within each group (i.e. baseline vs. 3 months). Assess insulin levels collecting blood samples in a fasting state. Insulin levels will be determined using commercially available equipment at a local laboratory (Roche Cobas e801). Measurements will be performed for between group comparison and within groups comparison to understand the effect of diets. 3 months
Secondary Effect of diets on insulin levels by comparing groups at 6 months of intervention (i.e. control low fat diet and the 2 keto groups) and changes over time within each group (i.e. baseline vs. 6 months). Assess insulin levels collecting blood samples in a fasting state. Insulin levels will be determined using commercially available equipment at a local laboratory (Roche Cobas e801). Measurements will be performed for between group comparison and within groups comparison to understand the effect of diets. 6 months
Secondary Effect of diets on hemoglobin A1C (HbA1c) levels by comparing groups at 3 months of intervention (i.e. control low fat diet and the 2 keto groups) and changes over time within each group (i.e. baseline vs. 3 months). Assess HbA1c collecting blood samples in a fasting state. HbA1c levels will be determined using commercially available equipment at a local laboratory (COBAS c513) and reported in percentage. Measurements will be performed for between group comparison and within groups comparison to understand the effect of diets. 3 months
Secondary Effect of diets on hemoglobin A1C (HbA1c) levels by comparing groups at 6 months of intervention (i.e. control low fat diet and the 2 keto groups) and changes over time within each group (i.e. baseline vs. 6 months). Assess HbA1c collecting blood samples in a fasting state. HbA1c levels will be determined using commercially available equipment at a local laboratory (COBAS c513) and reported in percentage. Measurements will be performed for between group comparison and within groups comparison to understand the effect of diets. 6 months
Secondary Effect of diets on ApoB100 levels by comparing groups at 3 months of intervention (i.e. control low fat diet and the 2 keto groups) and changes over time within each group (i.e. baseline vs. 3 months). Assess ApoB100 collecting blood samples in a fasting state. ApoB100 levels will be determined using commercially available equipment at a local laboratory (Siemens BNII Nephelometer). Measurements will be performed for between group comparison and within groups comparison to understand the effect of diets. 3 months
Secondary Effect of diets on ApoB100 levels by comparing groups at 6 months of intervention (i.e. control low fat diet and the 2 keto groups) and changes over time within each group (i.e. baseline vs. 6 months). Assess ApoB100 collecting blood samples in a fasting state. ApoB100 levels will be determined using commercially available equipment at a local laboratory (Siemens BNII Nephelometer). Measurements will be performed for between group comparison and within groups comparison to understand the effect of diets. 6 months
Secondary Effect of diets on immune function and Inflammation measured by blood Immune Markers by comparing groups at 3 months of intervention and changes over time within each group compared to baseline. In the fasting state, immune cell subset and activation states will be determined by flow cytometry using whole blood to quantify various immune cell phenotypes. Immune cells will be stained for T cell (CD3, CD4+, CD8+, CD45RA+, CD45RO+), Treg (FOXP3+), B cell (CD20), macrophage (CD14), NK cell (CD56+) and activation markers (CD11b+, CD25+, CD28+, CD86+). The quantification of cytokine secretion by immune cells stimulated with mitogens (phytohemagglutinin (PHA, a T cell mitogen) and lipopolysaccharide (LPS, an antigen-presenting cell stimulant)) is used to evaluate their effector function. Cytokines assessed in the supernatant include IL-1ß (only for LPS), IL-2 (only for PHA), IL-6, IL-10, IFN-?, and TNF-a for both mitogen. 3 months
Secondary Effect of diets on immune function and Inflammation measured by blood Immune Markers by comparing groups at 6 months of intervention and changes over time within each group compared to baseline. In the fasting state, immune cell subset and activation states will be determined by flow cytometry using whole blood to quantify various immune cell phenotypes. Immune cells will be stained for T cell (CD3, CD4+, CD8+, CD45RA+, CD45RO+), Treg (FOXP3+), B cell (CD20), macrophage (CD14), NK cell (CD56+) and activation markers (CD11b+, CD25+, CD28+, CD86+). The quantification of cytokine secretion by immune cells stimulated with mitogens (phytohemagglutinin (PHA, a T cell mitogen) and lipopolysaccharide (LPS, an antigen-presenting cell stimulant)) is used to evaluate their effector function. Cytokines assessed in the supernatant include IL-1ß (only for LPS), IL-2 (only for PHA), IL-6, IL-10, IFN-?, and TNF-a for both mitogen. 6 months
Secondary Effect of diets on inflammatory markers (C-reactive protein (CRP)) by comparing groups at 3 months of intervention (i.e. control low fat diet and the 2 keto groups) and changes over time within each group (i.e. baseline vs. 3 months). Assess levels of acute phase protein (CRP) collecting blood samples in a fasting state. CRP will be determined using commercially available equipment at a local laboratory (Roche Cobas c503). Measurements will be performed for between group comparison and within groups comparison to understand the effect of diets. 3 months
Secondary Effect of diets on inflammatory markers (C-reactive protein (CRP)) by comparing groups at 6 months of intervention (i.e. control low fat diet and the 2 keto groups) and changes over time within each group (i.e. baseline vs. 6 months). Assess levels of acute phase protein (CRP) collecting blood samples in a fasting state. CRP will be determined using commercially available equipment at a local laboratory (Roche Cobas c503). Measurements will be performed for between group comparison and within groups comparison to understand the effect of diets. 6 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2